Boehringer expands its crowdsourced research to include psychiatric R&D

Boehringer Ingelheim has expanded its crowdsourced R&D program into the field of psychiatric diseases, broadening its partnership with Germany's BioMed X to spotlight new therapies. Under a broadened agreement, Boehringer and BioMed X are inviting young neuroscientists from research outfits around the globe to submit proposals for projects that examine the biology of the brain, planning to pick the best and assemble a development team at a dedicated lab in the University of Heidelberg. Boehringer and BioMed X have established a similar relationship in COPD, finalizing a team in September. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.